{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-in-pregnancy/prescribing-information/labetalol/","result":{"pageContext":{"chapter":{"id":"9c20faa9-01df-51f3-8ea5-1cff9dc7ba12","slug":"labetalol","fullItemName":"Labetalol","depth":2,"htmlHeader":"<!-- begin field 3500e25a-84d5-4b6f-b5ef-869a254b8fd5 --><h2>Labetalol</h2><!-- end field 3500e25a-84d5-4b6f-b5ef-869a254b8fd5 -->","summary":"","htmlStringContent":"<!-- begin item 8d02a2e5-bc78-4ce0-ba16-37f033cbbf68 --><!-- end item 8d02a2e5-bc78-4ce0-ba16-37f033cbbf68 -->","topic":{"id":"6ecaddc4-ff30-5cf4-ad9e-1df6efa32f1b","topicId":"b42a4357-926e-40db-93be-eb2734585661","topicName":"Hypertension in pregnancy","slug":"hypertension-in-pregnancy","lastRevised":"Last revised in July 2020","chapters":[{"id":"be1a3062-ba16-5320-bc1f-7931438b3b5e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"37d79826-12c0-54a5-859c-f5aab239dccb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7ede8737-53eb-57a2-9db3-c67e7b595b36","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"000e1ae9-fec8-5c7e-93fa-aac37cbed3b1","slug":"changes","fullItemName":"Changes"},{"id":"6aee7a8f-5861-5cdc-98a3-6cca34fc56c0","slug":"update","fullItemName":"Update"}]},{"id":"a142cb05-c8c8-5f0b-a31f-aee4193f794a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fb45ed4d-238b-5c83-a4c9-503c743ce614","slug":"goals","fullItemName":"Goals"},{"id":"9fe5bf45-a5b8-5910-9d8c-6c7d392f1779","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"152c0aed-a09e-585e-be86-456cff579be0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e424db7c-6f59-5395-8125-3f64c8335e1c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"388966c0-e5d0-5421-b48f-b9c11780841e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"aa780aa5-6dd7-53a0-893d-5f60840b81a9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c2bcbadf-68d8-5fa9-8752-b5b9846e022a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"be8adaec-21d7-5658-acb7-9487648799b4","slug":"definition","fullItemName":"Definition"},{"id":"a31e2e01-f95d-55d6-a81d-9f251edbf121","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fe25ef6b-b112-589a-aa03-6f59c10bb254","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1cacb2e-13ff-5c3f-9767-77524f5938ad","slug":"prognosis","fullItemName":"Prognosis"},{"id":"5a7a190a-9065-5e86-a995-19f480ddc1ae","slug":"complications","fullItemName":"Complications"},{"id":"39c857d6-2892-50eb-926a-0e42813dfdc8","slug":"long-term-health-implications","fullItemName":"Long-term health implications"}]},{"id":"76ba09af-ee47-5bcc-9270-4189dc2521ea","fullItemName":"Management","slug":"management","subChapters":[{"id":"29858bb6-e45a-5a43-bcf6-707da3b7f93e","slug":"pre-eclampsia","fullItemName":"Scenario: Pre-eclampsia"},{"id":"a7e6503b-bdb3-5f87-8485-0352a165acbf","slug":"pre-existing-hypertension-or-hypertension-before-20-weeks","fullItemName":"Scenario: Pre-existing hypertension, or hypertension before 20 weeks"},{"id":"525f57d9-c730-5acb-bc09-7a9500642f44","slug":"new-hypertension-after-20-weeks","fullItemName":"Scenario: New hypertension after 20 weeks"},{"id":"4fae554e-dd42-5116-9621-ba14519b2cc7","slug":"proteinuria-no-hypertension-after-20-weeks","fullItemName":"Scenario: Proteinuria and no hypertension after 20 weeks"},{"id":"189d666f-8d4d-5259-9194-b51f622a899e","slug":"postpartum-follow-up","fullItemName":"Scenario: Postpartum follow-up"}]},{"id":"df72f6fc-57f8-59ce-863e-0aafbe952576","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d81aa3f7-0ac1-557e-aeb4-85c389e3d449","slug":"aspirin","fullItemName":"Aspirin"},{"id":"9c20faa9-01df-51f3-8ea5-1cff9dc7ba12","slug":"labetalol","fullItemName":"Labetalol"},{"id":"a8bfba7d-aa2a-58dd-8623-f94e9a11868e","slug":"methyldopa","fullItemName":"Methyldopa"},{"id":"80c4cdd6-918d-5b69-9052-a943de729d40","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"be2fc921-a370-593b-83f0-3adf0dbcb226","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4e8e53ad-14b2-51b1-b527-d41b79469ddf","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"766ae496-9560-5803-92fa-8d7f71dc073e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0306f0ee-51ab-53f0-bfba-47ceda06c33c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"204ea692-4044-51c2-b0d6-84f596e7ff27","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fe018251-2fcc-5a91-9662-fd930649403a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"961ee437-62d3-5138-83b6-d59d61ff6085","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a96b6bfe-8e8a-51bd-beb4-c719aab1df08","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"df72f6fc-57f8-59ce-863e-0aafbe952576","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"50fa7285-652f-5be5-b635-eaa1370708a4","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field a84df014-df95-4125-9446-20126ce2ab9f --><h3>Contraindications and cautions</h3><!-- end field a84df014-df95-4125-9446-20126ce2ab9f -->","summary":"","htmlStringContent":"<!-- begin item b230cce3-3a30-443f-92d8-2611e62f0aa6 --><!-- begin field 748c0ace-344b-4791-8612-bf55c12455e6 --><p><strong>Labetalol should not be prescribed to people with:</strong></p><ul><li>Asthma.</li><li>Uncontrolled heart failure.</li><li>Cardiogenic shock.</li><li>Sick sinus syndrome (including sino-atrial block, second or third degree heart block).</li><li>Prinzmetal's angina.</li><li>Phaeochromocytoma.</li><li>Metabolic acidosis.</li><li>Bradycardia.</li><li>Hypotension.</li><li>Severe peripheral circulatory disorders (Raynaud's disease, intermittent claudication).</li></ul><p><strong>Labetalol should be used with caution in people with:</strong></p><ul><li>Poor cardiac reserve.</li><li>Peripheral circulatory disorders (Raynaud's disease, intermittent claudication).</li><li>Diabetes mellitus.</li><li>Psoriasis.</li><li>History of hypersensitivity to allergens.</li><li>Myasthenia gravis.</li><li>Renal impairment — dose reduction should be considered.</li><li>Hepatic impairment — there have been rare reports of (usually reversible) severe hepatocellular injury with labetalol after both short and long term treatment. Liver function tests should be done at the first sign or symptom of liver dysfunction. If there is laboratory evidence of liver injury or the person is jaundiced, labetalol should be stopped and not re-started.</li><li>Ischaemic heart disease and first degree atrioventricular (AV) block — the course of labetalol should not be interrupted or discontinued abruptly.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 748c0ace-344b-4791-8612-bf55c12455e6 --><!-- end item b230cce3-3a30-443f-92d8-2611e62f0aa6 -->","subChapters":[]},{"id":"a1d6a9fb-a7f7-55bb-acd7-6062bb097134","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 07e3d83a-490a-4111-85c1-23f08d3a4b0a --><h3>Adverse effects</h3><!-- end field 07e3d83a-490a-4111-85c1-23f08d3a4b0a -->","summary":"","htmlStringContent":"<!-- begin item 2ba33b4d-d73d-42af-90c4-8fe4a85673fa --><!-- begin field 2826e809-a1c6-4bb4-b17d-5d6d09abde8b --><p><strong>Adverse effects of labetalol include:</strong></p><ul><li>Neurological — tiredness, weakness, headache.</li><li>Skin — rashes, tingling scalp, rarely lichenoid rash.</li><li>Gastrointestinal — epigastric pain, nausea, vomiting, liver damage.</li><li>Urological — difficulty in micturition.</li><li>Neuropsychiatric — depressed mood.</li><li>Other — postural hypotension, nasal congestion, sweating.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 2826e809-a1c6-4bb4-b17d-5d6d09abde8b --><!-- end item 2ba33b4d-d73d-42af-90c4-8fe4a85673fa -->","subChapters":[]},{"id":"b8b9a7d9-6cd7-5176-8110-43a2983b8469","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field d41fa230-4b6b-4314-a436-d72f330be449 --><h3>Drug interactions</h3><!-- end field d41fa230-4b6b-4314-a436-d72f330be449 -->","summary":"","htmlStringContent":"<!-- begin item e4ec3fc3-4f72-4e0b-8190-21e7196a8ca1 --><!-- begin field 518eb73d-d71c-4f69-913d-f3aba385e75d --><p><strong>Concomitant use of labetalol is contraindicated with:</strong></p><ul><li>Calcium antagonists such as verapamil and to a lesser extent diltiazem — may reduce cardiac contractility and atrio-ventricular conduction.</li><li>Digitalis glycosides — may increase cardiac atrio-ventricular conduction time.</li><li>Clonidine — beta-blocker use increases the risk of rebound hypertension.</li><li>Monoamineoxidase inhibitors (MAOIs) — except MOA-B inhibitors.</li></ul><p><strong>Combinations requiring caution include:</strong></p><ul><li>Class I anti-arrhythmic agents, for example disopyramide, quinidine; and the class III anti-arrhythmic drug amiodarone — may have potentiating effects on atrial conduction time and induce negative inotropic effect.</li><li>Insulin and oral hypoglycaemic drugs — may intensify the blood-sugar lowering effect, especially of non-selective beta-blockers. Beta blockade may prevent the appearance of signs of hypoglycaemia.</li><li>Cimetidine and hydralazine — may increase the bioavailability of labetalol.</li><li>Dihydropyridine derivates such as nifedipine — may increase the risk of hypotension. In people with latent cardiac insufficiency, treatment with beta-blockers may lead to cardiac failure.</li><li>Cyclo-oxygenase (COX)-inhibiting drugs — may decrease the hypotensive effect of beta-blockers.</li><li>Sympathomimetic agents (for example dopamine) — may counteract the effect of beta-blockers.</li><li>Tricyclic antidepressants — may increase the blood pressure lowering effect of labetalol and may increase the incidence of tremor.</li><li>Barbiturates, phenothiazines or other antihypertensive agents — may increase the blood pressure lowering effect of labetalol.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 518eb73d-d71c-4f69-913d-f3aba385e75d --><!-- end item e4ec3fc3-4f72-4e0b-8190-21e7196a8ca1 -->","subChapters":[]},{"id":"1835158f-701c-519f-90ea-68f1a6a0b5a7","slug":"dosing-information","fullItemName":"Dosing information","depth":3,"htmlHeader":"<!-- begin field f150da65-b505-4e8f-9b80-12207bfd2fc4 --><h3>Dosing information</h3><!-- end field f150da65-b505-4e8f-9b80-12207bfd2fc4 -->","summary":"","htmlStringContent":"<!-- begin item d813f8bd-4526-4a4c-bde4-ff487d279b7c --><!-- begin field f6aec1b5-49a5-4ccc-9072-39fd9506bc98 --><ul><li>Start with a dose of 100mg labetalol twice a day.</li><li>Increase the dose at fortnightly intervals if needed and tolerated.</li><li>Usual dose 200 mg twice daily, increased if necessary up to 800 mg daily in 2 divided doses, to be taken with food, higher doses to be given in 3–4 divided doses.</li><li>The maximum recommended dose is 2,400 mg daily.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field f6aec1b5-49a5-4ccc-9072-39fd9506bc98 --><!-- end item d813f8bd-4526-4a4c-bde4-ff487d279b7c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}